Company Information
CIN
Status
Date of Incorporation
19 June 2001
State / ROC
Pune / ROC Pune
Last Balance Sheet
31 March 2023
Last Annual Meeting
10 July 2023
Paid Up Capital
55,113,650
Authorised Capital
650,000,000
Directors
Sanjay Singh
Director/Designated Partner
over 2 years ago
over 2 years ago
Shailesh Kripalu Ayyangar
Director/Designated Partner
over 2 years ago
over 2 years ago
Sunil Rajanikant Mehta
Director/Designated Partner
over 2 years ago
over 2 years ago
Kavita Singh
Director/Designated Partner
over 2 years ago
over 2 years ago
Hitesh Sohanlal Jain
Director/Designated Partner
over 6 years ago
over 6 years ago
Satish Ramanlal Mehta
Director/Designated Partner
over 10 years ago
over 10 years ago
Sanjay Rajanikant Mehta
Director
over 21 years ago
over 21 years ago
Past Directors
Sachin Bhawanishankar Kaushik
Cfo
almost 5 years ago
almost 5 years ago
Gyan Chandra Mishra
Director
over 7 years ago
over 7 years ago
Girish Laxmikant Telang
Director
over 13 years ago
over 13 years ago
Samit Satish Mehta
Director
over 13 years ago
over 13 years ago
Shreekant Krushnaji Bapat
Director
over 16 years ago
over 16 years ago
Krishna Kumar Tewari
Director
over 17 years ago
over 17 years ago
Mukund Pandurang Ranade
Director
almost 23 years ago
almost 23 years ago
Arunkumar Purshotamlal Khanna
Director
over 24 years ago
over 24 years ago
Patents
The present invention provides a novel scalable and industrially viable downstream process for purification of recombinant human G CSF.
The present invention related to a process for the preparation of filgrastim of higher purity and yield using a novel multi steps liquid chromatographic method after the over-expression of the protein in prokaryotic cells. This invention makes use of a combination of ion exchange chromatographic resins in series hav...
The present invention relates to pharmaceutical compositions of tenecteplase that are safe and effective in the treatment of acute ischemic stroke compared with the known compositions. The advantages of the invention are its safety and efficacy over the known formulations in the treatment of acute ischemic stroke in...
The present invention relates to a process for the preparation of TNK-tPA by inoculating said seed culture for production phase in a perfusion mode/batch using adherent type Chinese Hamster Ovary cell with packed bed technology comprising of a modified CHO-S-SFM II production medium; wherein the residual glucose lev...
The present invention relates to a process for the preparation of a glycoprotein using adherent type substrate in perfusion-mode, wherein in the production phase, the monosaccharide content in the perfusing medium is 7 gm/day to 137.5 gm/day.
The present invention relates to a process for the preparation of rhGM-CSF by growing the yeast cells expressing rhGM-CSF in a suitable medium, which comprises of glycerol as a carbon source to yield the biomass and inducing the grown yeast cells capable of expressing the protein using alcohol in an incremental orde...
The present invention pertains to an ophthalmic composition of Bevacizumab, in a single use prefilled syringe which is safe, non-toxic and efficacious for administration during the shelf life, characterised in that the ophthalmic solution is controlled with respect to the number of sub-visible particulate matter wit...
The present invention relates to a novel, economically viable, storage stable, lyophilized composition of pegaspargase. The composition comprises pegaspargase, a cryoprotectant, a bulking agent, a buffer and may optionally contain other pharmaceutically acceptable excipients including but not limited to a salt. The ...
The present invention discloses a naïve antibody phage display library (APDL) a process for producing the same and a method of obtaining manufacturable antibodies as soluble Fabs from the antibody phage display library.
The present invention relates to a novel process of isolating and purifying tissue plasminogen activator and its variants more specifically TNK tPA from CHO cells and describes an industrially applicable simple cost effective robust and highly efficient process of TNK tPA purification.
The present invention pertains to an economic packed-bed perfusion system for the production of pharmaceutical grade of recombinant TNK-tPA. The present invention involves a cell culture process utilizing CHO cells more specifically in a micro/macro carriers based packed-bed perfusion system. The process of the pres...
The disclosed invention relates to a method for purifying a recombinant protein produced in the bacterial protein expression system. Specifically, it relates to the efficient purification of a therapeutic recombinant protein by removing the impurities from a complex liquid mixture containing said recombinant protein...
Lyophilised formulations of mRNA adsorbed onto lipid nano-emulsion particles. The present invention relates to lyophilised formulations of mRNA adsorbed onto lipid nano-emulsion particles. It particularly provides a method for lyophilisation of liquid formulations of mRNA adsorbed onto lipid nano-emulsion particles ...
RNA adsorbed onto lipid nano-emulsion particles and its formulations. The present invention relates, a method of preparing a liquid formulation of RNA complexed with lipid nano-emulsion particles or nano-carriers. It particularly provides a method for preparation of the RNA adsorbed onto lipid nano-emulsion particle...
A lyophilised COVID-19 vaccine formulation. The present invention relates, a method of preparing a lyophilized formulation of mRNA complexed onto lipid nano-emulsion particles or nano-carriers for intradermal application. It particularly provides a method for preparation of the mRNA adsorbed onto lipid nano-emulsion...
Registered Trademarks
[Class : 5] Pharmaceutical And Medicinal Preparations; Ayurvedic Preparations; Dietary Food Supplements For Medical Use; Dietetic Food Supplements Adapted For Medical Purposes; Health Food Supplements For Persons With Special Dietary Requirements; Medicated Food Supplements.
[Class : 5] Pharmaceutical And Medicinal Preparations; Ayurvedic Preparations; Dietary Food Supplements For Medical Use; Dietetic Food Supplements Adapted For Medical Purposes; Health Food Supplements For Persons With Special Dietary Requirements; Medicated Food Supplements.
[Class : 5] A Pharmaceutical Vaccine Preparation.
View +24 more Brands for Gennova Biopharmaceuticals Limited.
Charges
21 February 2018
Hdfc Bank Limited
15 Lak
23 August 2017
Hdfc Bank Limited
31 Lak
11 January 2017
Bank Of Maharashtra
22 Crore
11 January 2017
Bank Of Maharashtra
2 Crore
30 June 2004
The Bank Of Maharashtra Limited
12 Crore
23 March 2011
Biotechnology Industry Research Assistance Council
2 Crore
30 October 2017
Kotak Mahindra Bank Limited
13 Crore
24 March 2012
Biotechnology Industry Research Assistance Council
2 Crore
13 October 2011
Bank Of Maharashtra
24 Crore
10 July 2008
Citi Bank N.a.
13 Crore
03 March 2010
Biotechnology Industry Research Assistance Council
64 Lak
31 December 2009
State Bank Of India
19 Crore
02 September 2021
Bank Of Maharashtra
157 Crore
30 June 2021
Axis Bank Limited
90 Lak
25 June 2021
Export Import Bank Of India
22 Crore
30 October 2022
Citi Bank N.a.
0
20 May 2022
Axis Bank Limited
0
21 February 2018
Hdfc Bank Limited
0
02 September 2021
Others
0
30 June 2021
Axis Bank Limited
0
25 June 2021
Others
0
23 August 2017
Hdfc Bank Limited
0
30 October 2017
Others
0
11 January 2017
Others
0
11 January 2017
Others
0
10 July 2008
Citi Bank N.a.
0
31 December 2009
State Bank Of India
0
13 October 2011
Bank Of Maharashtra
0
24 March 2012
Biotechnology Industry Research Assistance Council
0
30 June 2004
The Bank Of Maharashtra Limited
0
03 March 2010
Biotechnology Industry Research Assistance Council
0
23 March 2011
Biotechnology Industry Research Assistance Council
0
30 October 2022
Citi Bank N.a.
0
20 May 2022
Axis Bank Limited
0
21 February 2018
Hdfc Bank Limited
0
02 September 2021
Others
0
30 June 2021
Axis Bank Limited
0
25 June 2021
Others
0
23 August 2017
Hdfc Bank Limited
0
30 October 2017
Others
0
11 January 2017
Others
0
11 January 2017
Others
0
10 July 2008
Citi Bank N.a.
0
31 December 2009
State Bank Of India
0
13 October 2011
Bank Of Maharashtra
0
24 March 2012
Biotechnology Industry Research Assistance Council
0
30 June 2004
The Bank Of Maharashtra Limited
0
03 March 2010
Biotechnology Industry Research Assistance Council
0
23 March 2011
Biotechnology Industry Research Assistance Council
0
30 October 2022
Citi Bank N.a.
0
20 May 2022
Axis Bank Limited
0
21 February 2018
Hdfc Bank Limited
0
02 September 2021
Others
0
30 June 2021
Axis Bank Limited
0
25 June 2021
Others
0
23 August 2017
Hdfc Bank Limited
0
30 October 2017
Others
0
11 January 2017
Others
0
11 January 2017
Others
0
10 July 2008
Citi Bank N.a.
0
31 December 2009
State Bank Of India
0
13 October 2011
Bank Of Maharashtra
0
24 March 2012
Biotechnology Industry Research Assistance Council
0
30 June 2004
The Bank Of Maharashtra Limited
0
03 March 2010
Biotechnology Industry Research Assistance Council
0
23 March 2011
Biotechnology Industry Research Assistance Council
0
Documents
Form MR-1-03042021_signed
Copy of letter of consent to act as Managing Director/ Whole time Director/Manager ; -30122020
Copy of shareholders resolution-30122020
Copy of board resolution-30122020
Copy of MGT-8-22122020
List of share holders, debenture holders;-22122020
Form MGT-7-22122020_signed
Form DIR-12-26112020_signed
Optional Attachment-(1)-26112020
Optional Attachment-(1)-12102020
Form DIR-12-12102020_signed
Evidence of cessation;-12102020
Declaration of the appointee director, Managing director, in Form No. DIR-2;-12102020
Form MGT-14-04102020_signed
Form DPT-3-01102020-signed
Form MGT-14-29092020_signed
Copy(s) of resolution(s) along with copy of explanatory statement under section 173-29092020
Form PAS-6-19092020_signed
Form DIR-12-19092020_signed
Form PAS-6-18092020_signed
Form AOC-4(XBRL)-18092020_signed
XBRL financial statements duly authenticated as per section 134 (including Board's report,auditor's report and other documents)-14092020
Optional Attachment-(4)-14092020
Optional Attachment-(2)-14092020
Optional Attachment-(1)-14092020
Optional Attachment-(3)-14092020
Form SH-7-29072020-signed
Copy of Board resolution authorizing redemption of redeemable preference shares;-06072020
Form DIR-12-05032020_signed
Notice of resignation;-05032020
